Skip to content
value.today

Nupathe Inc.

Total raised
$29 M
2 rounds on record
Latest round
$28 M
Oct 2012
First round on record
Aug 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Nupathe Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2012$28 MNo. 2$10 to $50 million

Nupathe Inc.: Raise no. 2, Oct 2012

Investors in this round

20 investors had bought by the notice of Nov 6, 2012: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Nupathe Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,230,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Armando Anido · Executive Officer, Director
  • Bart J. Dunn · Executive Officer
  • Gerald W. McLaughlin · Executive Officer
  • Keith A. Goldan · Executive Officer
  • Michael F. Marino · Executive Officer
  • Terri B. Sebree · Executive Officer
  • Brian J. Sisko · Director
  • James A. Datin · Director
  • Michael P. Cola · Director
  • Richard S. Kollender · Director
  • Robert P. Roche · Director
  • Wayne P. Yetter · Director
  • William J. Federici · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Swann LLC (CRD 39011) · broker-dealer Leerink Swann LLC (CRD 39011) · New York, New YorkSold in all US states, and outside the US
  • MTS Securities, LLC (CRD 104059) · broker-dealer MTS Securities, LLC (CRD 104059) · New York, New YorkSold in all US states, and outside the US

Signed by Keith A. Goldan, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 6, 2012. Read the notice at the SEC.

equity, optionsSEC
Aug 2011$1 MNo. 1Under $2 million

Nupathe Inc.: Raise no. 1, Aug 2011

Investors in this round

1 investor had bought by the notice of Aug 8, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Nupathe Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $31 M offered; $30 M still to sell
Smallest investment taken
$500,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ezra H. Felker · Executive Officer
  • Gerald W. McLaughlin · Executive Officer
  • Jane H. Hollingsworth · Executive Officer, Director
  • Keith A. Goldan · Executive Officer
  • Michael F. Marino · Executive Officer
  • Terri B. Sebree · Executive Officer
  • Gary J. Kurtzman · Director
  • Jeanne F. Cunicelli · Director
  • Michael F. Cola · Director
  • Robert P. Roche · Director
  • Wayne P. Yetter · Director
  • William J. Federici · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount sold represents the value of the amount of common stock (i) issued to the investor for payment of the commitment fee payable by the Issuer pursuant to the terms of the subject financing and (ii) sold to the investor as of the date hereof.”

Signed by Keith A. Goldan, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 8, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Nupathe Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2012).

    SEC Form D · Nov 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2012

That is all the official record says: Nupathe Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

16 named in official filings. Open an investor to see everything it has backed.

Investors in Nupathe Inc.
InvestorKindAmountRoundRoleSource
Battelle Ventures, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
BioAdvance Ventures L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2010)SEC Form 3
Birchmere Ventures III LPVenture capitalnot statednot statedHeld Series A and B preferred stock (Form 3, 2010)SEC Form 3
Birchmere Ventures III TSIB LPVenture capitalnot statednot statedHeld Series A and B preferred stock (Form 3, 2010)SEC Form 3
BV3 LLCOthernot statednot statedHeld Series A and B preferred stock (Form 3, 2010)SEC Form 3
BV3 Management LPFund or asset managernot statednot statedHeld Series A and B preferred stock (Form 3, 2010)SEC Form 3
BVP GP LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Ezra H. FelkerPersonnot statednot statedHeld Series B preferred stock (Form 3, 2010)SEC Form 3
Innovation Valley Partners, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Ivp GP, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Jane H. HollingsworthPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2010)SEC Form 3
Keith A. GoldanPersonnot statednot statedHeld Series B preferred stock (Form 3, 2010)SEC Form 3
Quaker BioVentures II LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Sabby Healthcare Volatility Master Fund, Ltd.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Sabby Management, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Safeguard Scientifics IncCompanynot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nupathe Inc.
NameRoleNamed in
Armando AnidoExecutive officerNov 2012
Bart J. DunnExecutive officerNov 2012
Gerald W. McLaughlinExecutive officerNov 2012
Keith A. GoldanExecutive officerNov 2012
Michael F. MarinoExecutive officerNov 2012
Terri B. SebreeExecutive officerNov 2012
Ezra H. FelkerExecutive officerAug 2011
Jane H. HollingsworthExecutive officerAug 2011
Armando AnidoDirectorNov 2012
Brian J. SiskoDirectorNov 2012
James A. DatinDirectorNov 2012
Michael P. ColaDirectorNov 2012
Richard S. KollenderDirectorNov 2012
Robert P. RocheDirectorNov 2012
Wayne P. YetterDirectorNov 2012
William J. FedericiDirectorNov 2012
Gary J. KurtzmanDirectorAug 2011
Jane H. HollingsworthDirectorAug 2011
Jeanne F. CunicelliDirectorAug 2011
Michael F. ColaDirectorAug 2011